Serum Institute To Launch India's First Cervical Cancer Vaccine
NDTV
The Drugs Controller General of India granted market authorisation to Serum Institute of India to manufacture the indigenously-developed India's first cervical cancer vaccine.
Serum Institute of India CEO Adar Poonawalla on Tuesday said the company plans to launch its indigenously-developed vaccine to treat cervical cancer in women later this year. For the first time there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and we thank the #DCGI@MoHFW_INDIA for granting approval today.
The Drugs Controller General of India (DCGI) on Tuesday granted market authorisation to Serum Institute of India (SII) to manufacture the indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer.
In response to the approval by the drug regulator, Poonawalla in a tweet said, "For the first time there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and we thank the #DCGI @MoHFW_INDIA for granting approval today."
